Therefore, we examined the effects of an inhibitor of AKT1 (siRNA) in the cancer cachexia models, and found that the expression of the Akt/FOXO3a signaling pathways had changed, with higher expression of MaFbx. This evidence concerns the gene FBXO32 and cancer.